Submission for OMB Review; Comment Request; Fogarty International Center CareerTrac, 37585-37586 [06-5883]
Download as PDF
<![CDATA[
37585
Federal Register / Vol. 71, No. 126 / Friday, June 30, 2006 / Notices
and system capacity to improve early
childhood services in their States.
This information will supplement and
enhance the MCHB’s current data
collection efforts by providing a
quantifiable, standardized, systematic
mechanism for collecting information
across the funded implementation
Respondents: The SECCS
implementation grantees (Title V
agencies) funded in 2005 and 2006 will
be the primary respondents of the
instrument. Approximately 60
implementation grantees will respond to
the MDS. The estimated response
burden is as follows:
grantees. For the 2005 cohort of
implementation grantees, the MDS will
be administered once in 2006 to gather
baseline data, and again in the second
year of implementation (2007) to gather
follow-up data on progress made. For
the 2006 cohort of grantees, the MDS
will be administered once in 2007.
Responses
per respondent
Number of
respondents
Cohort
Hours per
response
Total hour
burden
2005 Cohort .....................................................................................................
2006 Cohort .....................................................................................................
18
42
*2
1
2
2
72
84
Total ..........................................................................................................
60
........................
........................
156
* Data will be collected once in 2006 and once in 2007.
Written comments and
recommendations concerning the
proposed information collection should
be sent within 30 days of this notice to:
John Kraemer, Human Resources and
Housing Branch, Office of Management
and Budget, New Executive Office
Building, Room 10235, Washington, DC
20503.
Dated: June 23, 2006.
Cheryl R. Dammons,
Director, Division of Policy Review and
Coordination.
[FR Doc. E6–10272 Filed 6–29–06; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
rwilkins on PROD1PC63 with NOTICES_1
Submission for OMB Review;
Comment Request; Fogarty
International Center CareerTrac
Summary: Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the Fogarty
International Center (FIC), the National
Institutes of Health (NIH), has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on February 14,
2006, page 7780–7781, and allowed 60days for public comment. No comments
were received from this notification
regarding the cost and hour burden
estimates. One comment was received
suggesting that the Federal Government
should not be funding international
work until all Amercians are cared for.
We note that through partnerships in
training and research with scientists
from around the world, including those
in developing countries, we are able to
identify new strategies and new
VerDate Aug<31>2005
18:19 Jun 29, 2006
Jkt 208001
understandings of disease processes,
including for AIDS, TB, and chronic
diseases such as heart disease, that
affect all Americans. The purpose of this
announcement is to allow an additional
30 days for public comment. The
National Institutes of Health may not
conduct or sponsor, and the respondent
is not required to respond to, an
information collection that has been
extended, revised, or implemented on or
after October 1, 1995, unless it displays
a currently valid OMB control number.
Proposed Collection
Title: Fogarty International Center
CareerTrac.
Type of Information Collection
Request: New.
Need and Use of Information
Collection: This data collection system
is being developed to track, evaluate
and report short and long-term outputs,
outcomes and impacts of international
trainees involved in health research
training programs specifically tracking
this for at least ten years following
training by having trainees enter their
own data after they have completed the
program. The data collection system
provides a streamlined, Web-based
application permitting principal
investigators to record career
achievement progress by trainee on a
voluntary basis. FIC management will
use this data to monitor, evaluate and
adjust grants to ensure desired outcomes
are achieved, comply with OMB PART
requirements, respond to congressional
inquiries, and as a guide to inform
future strategic and management
decisions regarding the grant program.
Frequency of Response: Annual and
periodic.
Affected Public: None.
Type of Respondents: Principal
Investigators funded by Fogarty
International Center.
The annual reporting burden is as
follows:
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
Estimated Number of Respondents:
150.
Estimated Number of Responses per
Respondent: 15.
Average Burden Hours per Response:
50; and
Estimated Total Annual Burden
Hours Requested: 1125.
The annualized cost to respondents is
estimated at $87,939. There are no
Capital Costs to report. There are no
Operating or Maintenance Costs to
report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, New Executive
Office Building, Room 10235,
Washington, DC 20503.
Attention: Desk Office NIH. To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
E:\FR\FM\30JNN1.SGM
30JNN1
37586
Federal Register / Vol. 71, No. 126 / Friday, June 30, 2006 / Notices
instruments, contact Dr. Linda Kupfer,
Fogarty International Center, National
Institutes of Health, 16 Center Drive,
Building 16, Bethesda, MD 20892–6705
or call non-toll-free number 301–496–
3288 or e-mail your request, including
your address to kupferl@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
Dated: June 21, 2006.
Richard Miller,
Executive Officer, FIC, National Institutes of
Health.
[FR Doc. 06–5883 Filed 6–29–06; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
rwilkins on PROD1PC63 with NOTICES_1
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
A New Mouse Monoclonal Antibody
Against Human Microphthalmia
Transcription Factor (MITF)
Description of Technology:
Micropthalmia Transcription Factor
(MITF) plays an important role in
melanocyte development and melanoma
growth. MlTF is important for
embryonic development, regulating the
generation of pigment cells and
formation of melanomas and other
tumors. MITF is made in various
VerDate Aug<31>2005
16:30 Jun 29, 2006
Jkt 208001
isoforms that may play unique roles for
different organs during different
developmental periods. Additionally,
tissue MITF levels can serve as a
molecular marker for the diagnosis of
metastatic melanoma and therapeutic
response.
This technology involves the
generation of several novel mouse
monoclonal antibodies against a subdomain of an MITF fragment that is
cleaved during cell death. Importantly,
these antibodies cross-react with human
MITF. The antibody was raised by
immunizing mice that are incapable of
producing the MITF sub-domain used as
the antigen. Three (3) different ‘‘clones’’
of these antibodies are currently
available and their corresponding
hybridoma names are 6A5 (IgG1), 1D2
(IgG2a) and 3D1 (IgG2a).
Applications: (1) Novel mouse
monoclonal antibodies specific to a
domain of MITF as research material; (2)
Novel mouse monoclonal antibodies
that cross react with human MITF.
Market: The currently commercially
available MITF monoclonal antibodies
recognize a particular domain of MITF.
These have been made available by
several companies including
Neomarkers, Abcam, Biomeda
Corporation, and Calbiochem.
This antibody reacts with a different
sub-domain of MITF and cross reacts
with human MITF.
Development Status: The technology
is ready for the market.
Inventors: Dr. Heinz Arnheiter, Mr.
Wenfang Liu and Dr. Hideki Murakami.
Relevant Publications Related to
MITF:
1. LA Garraway, HR Widlund, MA
Rubin, G Getz, AJ Berger, S
Ramaswamy, R Beroukhim, DA Milner,
SR Granter, J Du, C Lee, SN Wagner, C
Li, TR Golub, DL Rimm, ML Meyerson,
DE Fisher, WR Sellers. ‘‘Integrative
genomic analyses identify MITF as a
lineage survival oncogene amplified in
malignant melanoma.’’ Nature 2005 Jul
7;436(7047):117–122.
2. SR Granter, KN Weilbaecher, C
Quigley, DE Fisher. ‘‘Role for
microphthalmia transcription factor in
the diagnosis of metastatic malignant
melanoma.’’ Appl Immunohistochem
Mol Morphol. 2002 Mar; 10(1):47–51.
Patent Status: HHS Reference No. E–
228–2006/0—Research Material
Availability: The inventor is no longer
accepting requests for the antibody; it
will now be solely available via a
Biological Material License (BML).
Licensing Contact: David A.
Lambertson, PhD.; 301/435–4632;
lambertsond@od.nih.gov.
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
Diamidine Inhibitors of Tdp1 as AntiCancer Agents
Description of Technology: Available
for licensing and commercial
development are methods and
compositions for treating cancer, using
novel compounds derived from
diamidine. Diamidine and its
derivatives are potent inhibitors of
tyrosyl-DNA-phosphodiesterase (Tdp1),
which may be useful in chemotherapy.
Camptothecins are effective
Topoisomerase I (Top1) inhibitors, and
two derivatives (Topotecan and
Camptosar) are currently approved for
treatment of ovarian and colorectal
cancer. Camptothecins damage DNA by
trapping covalent complexes between
the Top1 catalytic tyrosine and the 3’end of the broken DNA. Tdp1 repairs
Top1-DNA covalent complexes by
hydrolyzing the tyrosyl-DNA bond.
Thus, the presence and activity of Tdp1
can reduce the effectiveness of
camptothecins as anti-cancer agents. In
addition, Tdp1 repairs free-radicalmediated DNA breaks.
Inhibition of Tdp1 using diamidine or
its derivatives, may reduce repair of
DNA breaks and increase the rate of
apoptosis in cancer cells. In addition,
diamidine derivatives have the potential
to enhance the anti-neoplastic activity
of Top1 inhibitors, by reducing repair of
Top1-DNA lesions through inhibition of
Tdp1.
Development Status: Pre-clinical
stage.
Inventors: Yves Pommier and
Christophe Marchand (NCI).
Publications:
1. Z Liao et al. ‘‘Inhibition of human
Tyrosyl-DNA Phosphodiesterase (Tdp1)
by aminoglycoside antibiotics and
ribosome inhibitors.’’ Mol Pharmacol.
2006 Apr 17; Epub ahead of print,
doi:10.1124/mol.105.021865.
2. Y Pommier. ‘‘Camptothecins and
topoisomerase I: a foot in the door.
Targeting the genome beyond
topoisomerase I with camptothecins and
novel anticancer drugs: importance of
DNA replication, repair and cell cycle
checkpoints.’’ Curr Med Chem
Anticancer Agents. 2004 Sep; 4(5):429–
34. Review.
3. Y Pommier et al. ‘‘Repair of and
checkpoint response to topoisomerase I
mediated DNA damage.’’ Mutat Res.
2003 Nov 27;532(1–2):173–203. Review.
Patent Status: U.S. Provisional
Application No. 60/786,604 filed 27 Mar
2006 (HHS Reference No. E–165–2006/
0-US–01).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: David A.
Lambertson, PhD.; 301/435–4632;
lambertsond@od.nih.gov.
E:\FR\FM\30JNN1.SGM
30JNN1
]]>Agencies
[Federal Register Volume 71, Number 126 (Friday, June 30, 2006)]
[Notices]
[Pages 37585-37586]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-5883]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; Comment Request; Fogarty International
Center CareerTrac
Summary: Under the provisions of Section 3507(a)(1)(D) of the
Paperwork Reduction Act of 1995, the Fogarty International Center
(FIC), the National Institutes of Health (NIH), has submitted to the
Office of Management and Budget (OMB) a request for review and approval
of the information collection listed below. This proposed information
collection was previously published in the Federal Register on February
14, 2006, page 7780-7781, and allowed 60-days for public comment. No
comments were received from this notification regarding the cost and
hour burden estimates. One comment was received suggesting that the
Federal Government should not be funding international work until all
Amercians are cared for. We note that through partnerships in training
and research with scientists from around the world, including those in
developing countries, we are able to identify new strategies and new
understandings of disease processes, including for AIDS, TB, and
chronic diseases such as heart disease, that affect all Americans. The
purpose of this announcement is to allow an additional 30 days for
public comment. The National Institutes of Health may not conduct or
sponsor, and the respondent is not required to respond to, an
information collection that has been extended, revised, or implemented
on or after October 1, 1995, unless it displays a currently valid OMB
control number.
Proposed Collection
Title: Fogarty International Center CareerTrac.
Type of Information Collection Request: New.
Need and Use of Information Collection: This data collection system
is being developed to track, evaluate and report short and long-term
outputs, outcomes and impacts of international trainees involved in
health research training programs specifically tracking this for at
least ten years following training by having trainees enter their own
data after they have completed the program. The data collection system
provides a streamlined, Web-based application permitting principal
investigators to record career achievement progress by trainee on a
voluntary basis. FIC management will use this data to monitor, evaluate
and adjust grants to ensure desired outcomes are achieved, comply with
OMB PART requirements, respond to congressional inquiries, and as a
guide to inform future strategic and management decisions regarding the
grant program.
Frequency of Response: Annual and periodic.
Affected Public: None.
Type of Respondents: Principal Investigators funded by Fogarty
International Center.
The annual reporting burden is as follows:
Estimated Number of Respondents: 150.
Estimated Number of Responses per Respondent: 15.
Average Burden Hours per Response: 50; and
Estimated Total Annual Burden Hours Requested: 1125.
The annualized cost to respondents is estimated at $87,939. There
are no Capital Costs to report. There are no Operating or Maintenance
Costs to report.
Request for Comments: Written comments and/or suggestions from the
public and affected agencies are invited on one or more of the
following points: (1) Whether the proposed collection of information is
necessary for the proper performance of the function of the agency,
including whether the information will have practical utility; (2) The
accuracy of the agency's estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (3) Ways to enhance the quality, utility, and
clarity of the information to be collected; and (4) Ways to minimize
the burden of the collection of information on those who are to
respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
Direct Comments to OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, New Executive Office Building, Room 10235, Washington, DC
20503.
Attention: Desk Office NIH. To request more information on the
proposed project or to obtain a copy of the data collection plans and
[[Page 37586]]
instruments, contact Dr. Linda Kupfer, Fogarty International Center,
National Institutes of Health, 16 Center Drive, Building 16, Bethesda,
MD 20892-6705 or call non-toll-free number 301-496-3288 or e-mail your
request, including your address to kupferl@mail.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30 days
of the date of this publication.
Dated: June 21, 2006.
Richard Miller,
Executive Officer, FIC, National Institutes of Health.
[FR Doc. 06-5883 Filed 6-29-06; 8:45 am]
BILLING CODE 4140-01-M
